Black t wisted HMPE yarn

We are Avient. 6 B ET T E R TO G E TH E R : P O LYO NE A N D C L A R I A N T M A S T ER BATC H Key Financial Data (1) 2021E Sales $4.3 billion 2021E EBITDA $560 million 2021E Free Cash Flow $275 million 88% of EBITDA from specialty applications (1) As of April 30, 2021 webcast Synergies ($ millions) Three-Year Estimate Administrative $ 20 Sourcing 30 Operational 25 Total Synergies $ 75 7 C L A R I A N T C O S T S Y N ERG I E S • On-track to realize $45 million of expected synergies in 2021 – up from previous estimate of $35 million • Relentless focus on guiding principles for acquisition integration: safety first, employee collaboration and exceeding customer expectations • Future revenue synergies in excess of $50 million by 2025 are not part of these estimates and represent additional growth over the long term 8 • Barrier technology • Functional additives • Processing aids • Flame retardants • Light-weighting additives Complementary Technologies • Clariant’s approved formulations and certified facilities • Legacy PolyOne’s leading share in distribution channels Healthcare Solutions • Clariant’s position in SE Asia, Latin America, Germany & Italy • Legacy PolyOne’s position in U.S., Canada and China Regional Strengths • Solutions with Avient’s engineered materials customers • Avient’s distribution channels Segment Cross-selling C O M P L E M E NTA RY T E C H N O LOG I E S A N D C U S TO M ER S D R I V E R E V E N U E S Y N E RG I E S Revenue synergy opportunities in excess of $50MM by 2025 The complementary aspects of our combined businesses are unquestionable. S U S TA I NA B I L I T Y • Most recent Sustainability report substantially expanded disclosure on key environmental and social topics Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 26 Capex / Revenue 2021E (%) AV I E N T I S A SS E T L I G H T Avient Specialty Formulators Other Chemical/Specialty Companies 2 3 2 2 2 3 3 4 3 3 3 4 4 5 5 5 6 7 7 8 24 A vi e n t A vi e n t (E xc l.

Tuttavia non è in grado di fornire risposte ad ogni domanda, né di risolvere qualsiasi situazione. Tuttavia, il membro di una famiglia non può super visionare, né direttamente né indirettamente, un altro membro della famiglia, per via del potenziale conflitto di interessi e dell’apparente condizione di favoritismo. Se non ne hanno uno, seguite immediatamente le procedure di sicurezza locali.

Microsoft PowerPoint - Avient February IR Meetings AVIENT CORPORATION (NYSE: AVNT) F E B R U A R Y 1 7 - 1 8 , 2 0 2 1 I N V E S T O R M E E T I N G S H O S T E D B Y G O L D M A N S A C H S A N D M O R G A N S T A N L E Y D I S C L A I M E R 2 Forward-Looking Statements In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We are Avient. 4 B ET T E R TO G E TH E R : P O LYO NE A N D C L A R I A N T M A S T ER BATC H Key Data 2021E Sales $4.1 billion 2021E EBITDA $510 million 2021E Free Cash Flow $250 million 87% of EBITDA from specialty applications Innovation is the lifeblood of a specialty company. Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 25 Capex / Revenue 2021E (%) AV I E N T I S A SS E T L I G H T Avient Specialty Formulators Other Chemical/Specialty Companies 2 3 2 2 2 3 3 6 2 3 4 4 5 5 5 6 6 6 7 9 25 A vi e n t A vi e n t (E xc l.

Pro účely protikorupčních zákonů mezi vládní činitele patří: • Úředníci a zaměstnanci státní správy (federální, státní, místní), oddělení nebo agentury • Jakákoli osoba jednající v oficiálním pověření nebo jménem jakékoli vlády, oddělení nebo agentury • Politické strany, představitelé politických stran a kandidáti na veřejnou funkci • Úředníci a zaměstnanci komerčních podniků vlastněných vládou/státem nebo vládou/státem řízených komerčních podniků, včetně částečně vlastněných subjektů • Úředníci a zaměstnanci veřejných mezinárodních organizací, jako je Organizace spojených národů Identifikace veřejného činitele může být často zjevná, ale ne vždy. Někdy se jednotlivci nemusí považovat za vládní činitele nebo nemusí za ně být považováni ani vládou své země, ale mohou přesto splňovat definice výše uvedeného vládního činitele.

Ne küldjön nekünk bizalmas személyes információkat e-mailben. Tájékoztatjuk, hogy az alkalmazandó jogszabályok megkövetelhetik, hogy az https://edpb.europa.eu/about-edpb/board/members_en Avient meghatározott ideig megőrizze önéletrajzát, még abban az esetben is, ha Ön azt kéri, hogy az Avient ne vegye számításban az Ön jelentkezését. 8.

Microsoft PowerPoint - AVNT Nov Investor Meetings Update AVIENT CORPORATION I N V E S T O R M E E T I N G S (NYSE: AVNT) N O V E M B E R 2 0 2 1 D I S C L A I M E R 2 Forward-Looking Statements In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We are Avient. 6 B ET T E R TO G E TH E R : P O LYO NE A N D C L A R I A N T C O LO R Key Financial Data (1) 2021E Sales $4.75 billion 2021E EBITDA $580 million 87% of EBITDA from specialty applications (1) As of October 28, 2021 webcast Synergies ($ millions) Three-Year Estimate Administrative $ 20 Sourcing 30 Operational 25 Total Synergies $ 75 7 C L A R I A N T C O S T S Y N ERG I E S • On-track to realize $50 million of expected synergies in 2021 – up from earlier estimate of $35 million • Relentless focus on guiding principles for acquisition integration: safety first, employee collaboration and exceeding customer expectations • Future revenue synergies in excess of $50 million by 2025 are not part of these estimates and represent additional growth over the long term 8 • Barrier technology • Functional additives • Processing aids • Flame retardants • Light-weighting additives Complementary Technologies • Clariant’s approved formulations and certified facilities • Legacy PolyOne’s leading share in distribution channels Healthcare Solutions • Clariant’s position in SE Asia, Latin America, Germany & Italy • Legacy PolyOne’s position in U.S., Canada and China Regional Strengths • Solutions with Avient’s engineered materials customers • Avient’s distribution channels Segment Cross-selling C O M P L E M E NTA RY T E C H N O LOG I E S A N D C U S TO M ER S D R I V E R E V E N U E S Y N E RG I E S Revenue synergy opportunities in excess of $50M by 2025 The complementary aspects of our combined businesses are unquestionable. Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 31 Capex / Revenue 2021E (%) AV I E N T I S A SS E T L I G H T Avient Specialty Formulators Other Chemical/Specialty Companies 2 3 1 2 3 3 3 4 3 3 4 5 5 5 6 9 A vi e n t A vi e n t (E xc l.

We are Avient. 6 B ET T E R TO G E TH E R : P O LYO NE A N D C L A R I A N T M A S T ER BATC H Key Financial Data (1) 2021E Sales $4.3 billion 2021E EBITDA $560 million 2021E Free Cash Flow $275 million 88% of EBITDA from specialty applications (1) As of April 30, 2021 webcast Synergies ($ millions) Three-Year Estimate Administrative $ 20 Sourcing 30 Operational 25 Total Synergies $ 75 7 C L A R I A N T C O S T S Y N ERG I E S • On-track to realize $45 million of expected synergies in 2021 – up from previous estimate of $35 million • Relentless focus on guiding principles for acquisition integration: safety first, employee collaboration and exceeding customer expectations • Future revenue synergies in excess of $50 million by 2025 are not part of these estimates and represent additional growth over the long term 8 • Barrier technology • Functional additives • Processing aids • Flame retardants • Light-weighting additives Complementary Technologies • Clariant’s approved formulations and certified facilities • Legacy PolyOne’s leading share in distribution channels Healthcare Solutions • Clariant’s position in SE Asia, Latin America, Germany & Italy • Legacy PolyOne’s position in U.S., Canada and China Regional Strengths • Solutions with Avient’s engineered materials customers • Avient’s distribution channels Segment Cross-selling C O M P L E M E NTA RY T E C H N O LOG I E S A N D C U S TO M ER S D R I V E R E V E N U E S Y N E RG I E S Revenue synergy opportunities in excess of $50MM by 2025 The complementary aspects of our combined businesses are unquestionable. S U S TA I NA B I L I T Y • Most recent Sustainability report substantially expanded disclosure on key environmental and social topics Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 26 Capex / Revenue 2021E (%) AV I E N T I S A SS E T L I G H T Avient Specialty Formulators Other Chemical/Specialty Companies 2 3 2 2 2 3 3 4 3 3 4 4 4 5 5 5 5 6 7 8 23 A vi e n t A vi e n t (E xc l.

The Wilflex™ brand of inks emerged in the early 1960’s as screen printing on t-shirts gained popularity for self-expression allowing the Wilflex™ brand to gain global recognition.

Maxxam™ BIO bio-based polyolefins with cellulose fiber can be useful for applications such as automotive interiors (decorative parts, trunk side liners, pillars, T-cup holders), consumers products (table and kitchenware, household goods), and packaging caps and closures.